Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Depocyt Generic Name & Formulations
Legal Class
Rx
General Description
Cytarabine 50mg/vial; liposomal suspension for intrathecal administration; preservative-free.
Pharmacological Class
Antimetabolite.
How Supplied
Single-use vials (5mL)—1
Manufacturer
Depocyt Indications
Indications
Intrathecal treatment of lymphomatous meningitis.
Depocyt Dosage and Administration
Adult
See full labeling. Give intrathecally over 1–5 minutes. Administer dexamethasone 4mg twice daily for 5 days with each cycle of treatment. Induction: 50mg every 14 days for 2 doses (weeks 1 and 3). Consolidation: 50mg every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: 50mg every 28 days for 4 doses (weeks 17, 21, 25 and 29). Reduce dose to 25mg if neurotoxicity develops and discontinue if it persists.
Children
Not recommended.
Depocyt Contraindications
Contraindications
Active meningeal infection.
Depocyt Boxed Warnings
Not Applicable
Depocyt Warnings/Precautions
Warnings/Precautions
Chemical arachnoiditis; reduce symptoms with dexamethasone. Previous irradiation, cytotoxic chemotherapy. Monitor blood counts and for development of neurotoxicity. Renal and hepatic impairment. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Depocyt Pharmacokinetics
See Literature
Depocyt Interactions
Interactions
Increased risk of neurotoxicity with concomitant cranial/spinal irradiation or other intrathecal antineoplastics.
Depocyt Adverse Reactions
Adverse Reactions
See full labeling. Arachnoiditis, GI upset, headache, fever, neurological toxicity (myelopathy), hydrocephalus, elevated CSF protein and WBC, weakness, back pain, insomnia, blurred vision, anaphylactic reactions; others.
Depocyt Clinical Trials
See Literature
Depocyt Note
Not Applicable
Depocyt Patient Counseling
See Literature
